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The hepatic-lipase deficient patient did not suffer from hyperlipidaemia but had a distinct abnormality in his lipoprotein profile. He showed no reduction in the VLDL, to VLDL, conversion and the catabolic mechanisms for the removal of VLDL,, VLDL,, IDL and LDL were unaffected. There was a substantial decrease in the VLDL, to IDI, conversion and virtually no transfer to LDL was occurring ( Figure 2) . A similar phenomenon was seen in the hypothyroid patients who appeared to have a secondary hepatic-lipase deficiency that resulted in raised IDL levels, due to a failure to convert IDL to LDL efficiently. Thyroxine treatment increased hepatic-lipase activity, promoted the conversion of IDL to LDL and significantly reduced the circulating IDL level. The other changes in the IDL and LDI, metabolism in thyroid disease may be attributed to decreased activity of the LDL receptor as reported earlier by Thompson 
Molecular genetics of lipoproteinlipase deficiency
The first mutations that were described in the LPL gene occurred in a patient with undetectable LPL mass and activity in plasma and were a major deletion and a duplication [4] . Since this report in 1989, many different DNA-sequence alterations have been identified that cause LPL deficiency [5] . A summary of the sequence alterations that have been reported from our laboratories is shown in Figure 1 . As can be seen the majority of these were missense mutations, mostly in exons 4, 5 and 6. In most instances different mutations segregate in unrelated families and in distinct population groups.
An exception to this is the substitution of leucine for proline at amino acid 207 that constitutes approx. 73% of the mutant alleles in patients with LPI, deficiency from Quebec, Canada [6] . The prevalence, spatial distribution and genealogy of this mutation in the Quebec population have been determined [7] . Genealogical reconstruction traced this mutation to 16 founders, all of whom migrated to Quebec in the early 17th century from the northwestern part of France, especially from the regions of Perche.
Another 
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resulting from an insertion of 5'-GGGCT-3' at residue 102 results in a premature stop codon in exon 4 and a truncated protein is formed [16] . This truncated LPI, protein is not detectable with the 5D2 monoclonal antibody that has epitope specificity for residue 400 in the C-terminal portion of the LPL protein [23] . Another frameshift mutation at the 3' end of exon 5 is due to the insertion of 5'-TAAATATT-3' after the second nucleotide of codon 229. This mutation results in a frameshift as well that is expected to produce a truncated protein of 238 residues, including nine foreign residues at its C terminal [23, 241 .
The phenotype of lipoprotein-lipase deficiency
In the search for naturally occurring mutations in the LPL gene, the phenotype chosen for study has been chylomicronaemia. Therefore it is not surprising that patients who were shown to have mutations causing LPL deficiency presented with the classical phenotype of chylomicronaemia, often presented in infancy with abdominal pain, hepatosplenomegaly or failure to thrive. Some patients also develop eruptive xanthomas and lipaemia retinalis. The preliminary assessment of mutations in the LPL gene revealed that these mutations were almost always associated with a significant clinical phenotype. However, we and others have described a mutation at residue 447 that is a C-G transversion that results in a premature termination codon at residue Ser,,, [ 11, 251. As a result the two C-terminal amino acids (Ser-Gly) are deleted from the mature protein. Despite this LPL retains most of its catalytic activity towards triacylglycerol. Therefore DNA changes in the LPL gene may be associated with completely defective LPL activity or with only a minor impairment of LPL catalytic activity. This reinforces the importance of performing in-vitro mutagenesis studies on any exonic DNA alteration in the LPL gene to try to determine whether these DNA changes represent functional defects or are DNA polymorphisms.
Mutations in the LPL gene may be associated also with partial LPL activity and a milder clinical phenotype. We have reported recently a mutation in the LPL gene that results in a defective LPL with partial residual activity [ 141. Interestingly this nucleotide 770 in exon 5 that resulted in an aminoacid substitution of cysteine for serine at residue 172. In-vitro mutagenesis showed that this mutation had approx. 6% of the normal LPL enzymatic activity, which was significantly higher than that seen in other LPL-gene mutations previously identified in our laboratory. This mutation occurs in a residue highly conserved in LPL, pancreatic lipase and hepatic lipase. Nevertheless data reported suggest that this mutation in the LPL gene may result in partial activity that could manifest with only mild hypertriglyceridaemia. Different environments that either increase VLDL secretion and/or further decrease LPL activity may precipitate chylomicronaemia in these patients. These environmental triggers could include pregnancy, oestrogen therapy, or possibly alcohol intake, diabetes or Badrenergic blocking agents.
Summary
We have described a large number of different mutations in the LPI, gene that result in completely catalytically defective LPL protein. More recently exonic polymorphisms in the LPL gene have been described that do not result in the catalytic activity of LPL being significantly impaired. Furthermore we have recently described a patient who is homozygous for a mutation in the LPL gene in a conserved region of exon 5 that results only in partial residual activity and a very mild clinical phenotype. This may suggest that the frequency of mutations in the LPL gene is greater than has been previously recognized.
Recognition and selection of patients for analysis was based on the phenotype of chylomicronaemia. However, the existence of the Ser,,,-Cys mutation in the LPL gene that results in only moderate hypertriglyceridaemia in the absence of environmental factors might suggest that mutations in this gene are more frequent and could be seen in patients with a milder clinical phenotype. The clue to detecting these changes in the LPL gene might be to investigate patients who present with chylomicronaemia due to different environmental triggers while, in the absence of these environmental factors, they have only moderate hypertriglyceridaemia.
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